49 89 6279 0
Sector(s): Basic Materials
Industry: Specialty Chemicals
Full-time employees: 15,725
|Dr. Christian Hartel||CEO, Pres & Member of Exec. Board||1.48M||N/A||1971|
|Dr. Tobias Ohler||CFO & Member of the Exec. Board||1.26M||N/A||1971|
|Mr. Auguste Willems||Member of Exec. Board||1.25M||N/A||1956|
|Ms. Angela Worl||Head of Human Resource, Personnel Director & Member of Exec. Board||616.1k||N/A||1967|
|Mr. Rainald Hagenhues||Head of Corp. Accounting & Tax||N/A||N/A||N/A|
|Mr. Joerg Hoffmann C.F.A.||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Goetz Neumann||Head of Legal Affairs||N/A||N/A||N/A|
|Mr. Jörg Hettmann||Head of Corp. Communications||N/A||N/A||N/A|
|Dr. Thomas Koini||Head of Sales & Distribution||N/A||N/A||N/A|
|Mr. Volker Radius||Head of Corp. Engineering||N/A||N/A||N/A|
Wacker Chemie AG, together with its subsidiaries, provides chemical products worldwide. It operates through four divisions: Wacker Silicones, Wacker Polymers, Wacker Biosolutions, and Wacker Polysilicon. The Wacker Silicones division offers silanes, siloxanes, silicone fluids, silicone emulsions, silicone elastomers, silicone resins, and pyrogenic silicas. The Wacker Polymers division provides binders and polymeric additives, such as dispersible polymer powder and vinyl acetate-ethylene dispersions, which are used in construction, paper, adhesive, paint, coating, and basic chemical industries. The Wacker Biosolutions division offers customized biotech and catalog products for fine chemicals, such as pharmaceutical proteins, vaccines, cyclodextrins, cysteine, polyvinyl acetate solid resins, and acetylacetone for pharmaceutical actives, food additives, and agrochemicals. The Wacker Polysilicon division produces hyperpure polysilicon for use in semiconductor and solar sectors. Wacker Chemie AG was founded in 1914 and is headquartered in Munich, Germany. The company operates as a subsidiary of Dr. Alexander Wacker Familiengesellschaft mbH.
Wacker Chemie AG’s ISS governance QualityScore as of 1 March 2023 is 7. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 6; Compensation: 6.